NYSE:PRX - Par Pharmaceutical Companies Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The Company operates primarily in the United States as two business segments: Par Pharmaceutical (Par), its generic products division, and Strativa Pharmaceuticals (Strativa), its branded products division. In February 17, 2012, the Company acquired Edict Pharmaceuticals Private Limited. On November 17, 2011, it acquired Anchen Incorporated and its subsidiary, Anchen Pharmaceuticals, Inc. In October 2011, it acquired rights to three products from Teva Pharmaceuticals in connection with Teva's acquisition of Cephalon. In September 2012, certain affiliates of TPG acquired the Company.

Receive PRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Par Pharmaceutical Companies (NYSE:PRX) Frequently Asked Questions

What is Par Pharmaceutical Companies' stock symbol?

Par Pharmaceutical Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRX."

Has Par Pharmaceutical Companies been receiving favorable news coverage?

News coverage about PRX stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Par Pharmaceutical Companies earned a daily sentiment score of -1.9 on InfoTrie's scale. They also assigned press coverage about the healthcare company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.

What other stocks do shareholders of Par Pharmaceutical Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Par Pharmaceutical Companies investors own include Gol Linhas Aereas Inteligentes (GOL), Wildhorse Resource Development (WRD), Baidu (BIDU), Amicus Therapeutics (FOLD), U.S. Global Investors (GROW), Inovio Pharmaceuticals (INO), Monster Beverage (MNST), Rite Aid (RAD), Rock-Tenn (RKT) and Broadcom (AVGO).

Who are Par Pharmaceutical Companies' key executives?

Par Pharmaceutical Companies' management team includes the folowing people:
  • Paul V. Campanelli, Chief Executive Officer (Age 54)
  • Michael A. Tropiano, Chief Financial Officer, Executive Vice President (Age 57)
  • Terrance John Coughlin, Chief Operating Officer (Age 52)
  • Thomas J. Haughey, Chief Administrative Officer, General Counsel (Age 51)

How do I buy shares of Par Pharmaceutical Companies?

Shares of PRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Par Pharmaceutical Companies' official website?

The official website for Par Pharmaceutical Companies is http://www.parpharm.com/.

How can I contact Par Pharmaceutical Companies?

Par Pharmaceutical Companies' mailing address is 1 Ram Ridge Rd, CHESTNUT RIDGE, NY 10977-6714, United States. The healthcare company can be reached via phone at +1-845-5735500.

MarketBeat Community Rating for Par Pharmaceutical Companies (NYSE PRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  89 (Vote Underperform)
Total Votes:  189
MarketBeat's community ratings are surveys of what our community members think about Par Pharmaceutical Companies and other stocks. Vote "Outperform" if you believe PRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/22/2019 by MarketBeat.com Staff

Featured Article: Municipal Bonds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel